Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 6/20 | 0.53 |
| ▸ | JAK2 | O60674 | 3/20 | 0.53 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30860966 | 1.00 | PDPK1 (0.53) | PDPK1JAK2AXLFGFR1FGFR2 | |
| SCHEMBL2467763 | 0.84 | JAK2 (0.53) | PDPK1JAK2AXLKDM4EMEN1 | |
| SCHEMBL29644080 | 0.84 | JAK2 (0.53) | PDPK1JAK2AXLKDM4EMEN1 | |
| SCHEMBL922069 | 0.81 | PDPK1 (0.65) | PDPK1JAK2AXLFGFR1FGFR2 | |
| SCHEMBL14755254 | 0.76 | AXL (0.49) | PDPK1JAK2AXLFGFR1FGFR2 | |
| SCHEMBL445902 | 0.76 | FGFR1 (0.50) | PDPK1JAK2AXLFGFR1FGFR2 | |
| SCHEMBL588513 | 0.76 | AXL (0.50) | PDPK1JAK2AXLFGFR1FGFR2 | |
| SCHEMBL15529807 | 0.76 | GSK3B (0.48) | PDPK1JAK2GSK3BPARP1ALDH1A1 | |
| SCHEMBL18764465 | 0.76 | PDPK1 (0.44) | PDPK1JAK2AXLFGFR1FGFR2 | |
| SCHEMBL2926172 | 0.76 | AXL (0.49) | PDPK1JAK2AXLFGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | claimed |
| WO-2025129167-A1 | INHIBITORS OF THE SURFACE EXPRESSION OF THE VOLTAGE-GATED SODIUM ION CHANNEL 1.7 (NAV1.7) AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-6027538-A | OXIDATION DYEING OF KERATINOUS FIBERS CONTAINING AT LEAST ONE COUPLER SELECTED FROM INDAZOLEAMINE DERIVATIVES AND AT LEAST ONE OXIDATION BASE; POWERFUL, NOT VERY SELECTIVE HAIR DYES WHICH ARE CAPABLE OF GENERATING INTENSE COLOR | L'OREAL S.A. (FR) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | PDPK1 42/4885JAK2 352/4885AXL 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.